Description of the medicine: Montelukast (Montelukast)
Sodium salt 1 - [[[((R) -m - [(E) -2- (7-chloro-2-quinolyl) vinyl] -α- [o- (1-hydroxy-1-methylethyl) phenethyl] benzyl ] thio] methyl] cyclopropane acetate.
Synonym: Singular, Singular.
A new bronchodilator drug, similar in action to zafirlukast (acolate). Like zafirlukast, it is a leukotriene receptor blocker (LTS 4 , LTD 4 , LTE 4 ) and has a bronchodilating and anti-inflammatory effect in bronchial asthma and other bronchospastic conditions.
When taken orally, it is rapidly and completely absorbed, bioavailability is about 70%, C max -2-3 hours; undergoes biotransformation in the liver, excreted by the kidneys.
The main indications for the use of montelukast are the prevention and long-term treatment of bronchial asthma. For the relief of asthma attacks, including asthmatic status, the drug is not used.
Assign to adults and adolescents (15 years and older) inside in the form of tablets of 0.01 g (10 mg) once a day (in the evening). Children aged 6-15 years are recommended in the form of chewable tablets of 0.005 g (5 mg) once a day (in the evening). For children under 5 years of age, the drug is not prescribed (due to lack of necessary data).
Montelukast is usually well tolerated. Possible headache, dyspeptic symptoms, swelling of the nasal mucosa, cough, increased activity (induction) of liver enzymes.
Contraindicated in pregnancy, breast-feeding, under the age of 6 years.
Treatment with montelukast, like other leukotriene inhibitors and generally new drugs, should be carried out under medical supervision. It is necessary to have ready means of quick relief of bronchospasm in case of their occurrence. Montelukast replacement of other drugs (glucocorticosteroids, etc.) should be done gradually. Caution is required when prescribing to patients with impaired liver function.
In connection with the potential induction of liver enzymes (cytochrome P-450), the possibility of changing the pharmacokinetics (with decreasing activity) of a number of drugs - theophylline, coumarin anticoagulants, terfenadine, etc. should be taken into account.
Method of release: tablets of 0.01 g (10 mg); chewable tablets of 0.005 g (5 mg) (N. 7, 14, 28).
Storage: List B, at a temperature of +15 to +30 ° C in a dry, dark place.